Method of weight loss and maintenance of skeletal muscle quantity
Skeletal muscle mass during weight loss was solved by using 5-[(2,4-dinitrobenoxy)methyl]-1-methyl-2-nitro-1H-imidazole as a controlled metabolic accelerator Maintaining the problem, achieving safe and efficient fat loss and muscle mass maintenance, reduces the risk of progression of obesity and related metabolic diseases.
Patent Information
- Application Number
- CN202380029099.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-04
- Filing Date
- 2023-02-06
- Publication Date
- 2024-11-08
AI Technical Summary
During weight loss, it is difficult for the prior art to effectively maintain skeletal muscle mass, and known uncoupling agents such as 2,4-dinitrobenol (DNP) have a high adverse effect rate and cannot be used safely.
5-[(2,4-dinitrobenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is used as a controlled metabolic accelerator to improve cell metabolism by increasing mitochondrial proton leakage and Reduce fat accumulation and maintain skeletal muscle mass.
This method significantly reduces fat accumulation during weight loss, reduces the risk of progression of obesity, hypertension and diabetes, while maintaining or increasing muscle mass, reducing muscle function damage, and shows higher safety compared to the placebo group and tolerate.
Smart Images

Figure CN118922187A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This International PCT Application claims priority to and the benefit of U.S. Provisional Application No. 63 / 307,506, filed on February 7, 2022, and U.S. Provisional Application No. 63 / 382,456, filed on November 4, 2022, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0002] The present disclosure relates to a method of maintaining skeletal muscle mass during weight loss. Background Art
[0003] Obesity is a well-known risk factor for the development of many common diseases, such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Obesity is best viewed as any degree of excessive fat gain that confers health risks. Weight loss is an indispensable therapy for people with obesity because it can improve the risk of developing complications such as heart disease, liver disease, pancreatic disease, kidney disease, etc. One of the main challenges of weight loss is maintaining skeletal muscle mass. The potential health benefits of weight loss induced by bariatric surgery or diet may be compromised by the associated loss of lean body mass. Cava et al., "Preserving healthy Muscle during Weight Loss", 2017Advances in Nutrition, 8(3): pp. 511–519; Zamboni et al. "Sarcopenic Obesity", 2021Sarcopnia, pp. 147-156. The risk of low muscle mass and impaired muscle function may also increase the risk of further complications. Therefore, there is a great need for a method of weight loss that can also help maintain skeletal muscle mass.
[0004] The use of chemical uncouplers of mitochondria as a means of reducing fat deposition has been a scientific goal for many years. Although there are several small molecules that decouple mitochondrial oxidative phosphorylation, the most well-known is 2,4-dinitrophenol (DNP). Although DNP uncoupling is known to have a robust effect, unfortunately, it is associated with an unacceptably high rate of significant adverse effects (J. Med. Toxicol. September 2011; 7 (3): 205-212). These adverse effects may include hyperthermia, tachycardia, sweating and tachypnea, ultimately leading to death. As a small, highly permeable lipophilic acid, DNP is rapidly absorbed in the stomach. High concentrations are rapidly distributed and uncoupled immediately, thereby generating high levels of heat in a short period of time. Therefore, DNP has a small therapeutic index and is extremely dangerous when overdosed. The Federal Food, Drug and Cosmetic Act of 1938 labeled DNP as "extremely dangerous and unfit for human consumption." Therefore, there is a need for uncouplers that can safely treat mitochondrial-related disorders or conditions.
[0005] 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is a new type of small molecule uncoupler (Compound 1). It acts as a controlled metabolic accelerator (CMA). It is designed to effectively solve the root cause of metabolic diseases, namely the accumulation of fat and sugars in the body. CMA is committed to improving cellular metabolism and increasing energy expenditure and calorie consumption, thereby reducing fat accumulation. Using a new controlled and targeted approach, Compound 1 can increase mitochondrial proton leak, which is an ongoing process in the body that dissipates energy and accounts for 20%-40% of daily calories. Compound 1 takes full advantage of the uncoupling mechanism of mitochondria to increase substrate utilization.
[0006] In recent years, an increase in the incidence and prevalence of muscle wasting in the obese population has been observed. In patients with obese sarcopenia, the preservation of muscle mass is crucial, and muscle mass loss is not only counterproductive to regaining metabolic health in these patients, but may also be a direct cause of subsequent morbidity and decreased quality of life due to falls, and increased dependency on daily care. Therefore, pharmacological interventions that can address excessive adiposity without deleterious effects on muscle mass are urgently needed. Summary of the invention
[0007] In one embodiment, the present disclosure provides a method of maintaining skeletal muscle mass during weight loss in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.
[0008] In another embodiment, the weight loss is due to fat loss.
[0009] In another embodiment, the subject suffers from obesity, excess body fat, diabetes, high blood pressure (hypertension), dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.
[0010] In another embodiment, the subject suffers from a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
[0011] In another embodiment, the subject suffers from decreased muscle mass or obese sarcopenia.
[0012] In another embodiment, the subject has a body mass index greater than 28 kg / m2.
[0013] In another embodiment, the therapeutically effective amount of Compound 1 is about 30 mg / day to about 1400 mg / day, about 50 mg / day to about 100 mg / day, about 150 mg / day to about 600 mg / day, or 200 mg to 550 mg orally once daily.
[0014] In another embodiment, the subject experiences greater than 5%, 10%, 20%, 30%, or 40% fat loss.
[0015] In one embodiment, the method slows the progression of obesity, hypertension, or diabetes. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 A flow chart of the Phase 2 study design is shown.
[0017] Figure 2 Shown are changes in body fat mass in the FAS group.
[0018] Figure 3 Shown are changes in body fat in the elevated HbA1c group.
[0019] Figure 4 The reduction in glycated albumin (percent %) in the total (FAS) population is shown.
[0020] Figure 5 Shown are changes in skeletal muscle mass and fat mass in the FAS group.
[0021] Figure 6 Shown are changes in skeletal muscle mass and fat mass among the HbA1c groups. DETAILED DESCRIPTION definition
[0022] Although various embodiments and aspects of the present invention are shown and described herein, it is obvious to those skilled in the art that such embodiments and aspects are provided only as examples. Without departing from the present invention, those skilled in the art will appreciate that many variations, changes and replacements are provided. It should be understood that the various alternatives of the embodiments of the present invention described herein may be used to practice the present invention.
[0023] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents or portions of documents cited in this application (including but not limited to patents, patent applications, articles, books, manuals, and treatises) are expressly incorporated by reference in their entirety for any purpose.
[0024] 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is a new type of small molecule uncoupler. It has the following structure:
[0025] 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole can be prepared by the procedure described in WO 2018 / 129258.
[0026] In the present disclosure, the terms Compound 1 and CM1 are interchangeable. They both refer to 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole.
[0027] As used herein, the term "a" or "an" means one or more.
[0028] The terms "include," "comprising," and "having" and their derivatives are used interchangeably herein as comprehensive, open-ended terms. For example, the use of "include," "including," or "having" means that any elements included, having, or included are not the only elements covered by the subject of the clause containing the verb.
[0029] As used herein, the term "about" means a range of values including a specified value that one of ordinary skill in the art would consider to be reasonably similar to the specified value. In some embodiments, the term "about" means within the standard deviation of measurements generally acceptable using the art. In some embodiments, "about" means a range extending to + / -10%, + / -5%, or + / -2% of a specified value. In some embodiments, "about" means a specified value.
[0030] As used herein, "treatment" or "treating" or "alleviation" or "improvement" or "mitigation" are used interchangeably herein. These terms refer to methods for obtaining beneficial or desired results, including, but not limited to, therapeutic benefit. Therapeutic benefit means eradication or amelioration of the underlying disorder being treated. In addition, therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, although the subject may still be suffering from the underlying disorder. Treatment includes causing a slowing of the development of clinical symptoms of the disease by administering the composition; suppressing the disease, i.e., causing a reduction in the clinical symptoms of the disease; inhibiting the disease, i.e., preventing the development of clinical symptoms by administering the composition after the initial onset of symptoms; and / or relieving the disease, i.e., causing their regression by administering the composition after the initial onset of clinical symptoms.
[0031] "Patient" or "subject" or "subject in need thereof" refers to a living organism suffering from or susceptible to a disease or condition that can be treated using the methods provided herein. The term does not necessarily indicate that the subject has been diagnosed with a particular disease, but typically refers to an individual under medical supervision. Non-limiting examples include humans, other mammals.
[0032] As used herein, "administering" a disclosed compound encompasses delivering a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, to a subject using any suitable formulation or route of administration (eg, as described herein).
[0033] "Pharmaceutically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.
[0034] As used herein, the term "pharmaceutically acceptable salts" refers to salts of the administered compound prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates, hydrates and clathrates thereof.
[0035] An "effective amount" is an amount sufficient to achieve the purpose (e.g., to achieve the effect of its administration, to treat a disease, to reduce enzyme activity, to alleviate one or more symptoms of a disease or condition, to reduce viral replication in a cell). An example of an "effective amount" is an amount sufficient to facilitate the treatment of a disease or alleviate one or more symptoms of a disease, which may also be referred to as a "therapeutically effective amount". "Relief" of one or more symptoms (and grammatical equivalents of this phrase) means a reduction in the severity or frequency of one or more symptoms or the elimination of one or more symptoms. Efficacy may also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount may have an effect of at least 1.2 times, 1.5 times, 2 times, 5 times, or more, compared to a control.
[0036] As used herein, the term "elevated body temperature" of a subject refers to an increase in body temperature associated with deleterious effects on the subject, including but not limited to illness, physical discomfort or pain, coma, and death. In a non-limiting embodiment, a significant increase in body temperature is an increase of about 0.5°C, about 1°C, about 1.5°C, about 2°C, about 2.5°C, about 3°C, about 3.5°C, about 4°C, about 4.5°C, about 5°C, about 5.5°C, about 6°C or more.
[0037] As used herein, HbA1c refers to hemoglobin A1c; MMRM refers to mixed model repeated measures. Negative values indicate a decrease in the parameter value.
[0038] Treatment
[0039] In one aspect, disclosed herein is a method for maintaining skeletal muscle mass during weight loss in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.
[0040] In another aspect, disclosed herein is a method for treating fibrosis, progressive fibrosis, or progressive fibrosing liver disease NASH in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.
[0041] In one embodiment, the weight loss is due to fat loss.
[0042] In another embodiment, the subject has obesity, excess body fat, diabetes, high blood pressure (hypertension), dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.
[0043] In another embodiment, the subject suffers from obesity or excess body fat.
[0044] In another embodiment, the diabetes is type 2 diabetes mellitus (T2DM).
[0045] In another embodiment, the subject suffers from a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
[0046] In another embodiment, the subject suffers from sarcopenia. Sarcopenia is an age-related loss of muscle mass and decreased muscle strength. An increase in the amount of adipose tissue is often associated with sarcopenia, a condition known as sarcopenic obesity. Symptoms of sarcopenia may include, but are not limited to, falls, muscle weakness, slow walking speed, self-reported muscle wasting, or difficulty performing normal daily activities.
[0047] In another embodiment, the subject suffers from decreased muscle mass or sarcopenic obesity.
[0048] In certain embodiments, the subject suffers from at least one symptom selected from the group consisting of decreased exercise tolerance, fatigue, tiredness, increased recovery time after exercise, and ankle swelling.
[0049] In another embodiment, the subject has abnormal HbA1c levels.
[0050] In another embodiment, the subject has an elevated HbA1c level greater than 5.7.
[0051] In certain embodiments, the subject has a high body mass index (BMI).
[0052] In another embodiment, the subject has a body mass index greater than 28 kg / m2.
[0053] In certain embodiments, the subject has a BMI between 28.0-45.0 kg / m2.
[0054] In certain embodiments, the subject has fibrosis or progressive fibrosis.
[0055] In certain embodiments, the subject has the progressive fibrosing liver disease NASH.
[0056] In certain embodiments, the therapeutically effective amount is about 30 mg / day to about 1400 mg / day, about 100 mg / day to about 1000 mg / day, about 150 mg / day to about 600 mg / day, 200 mg to 550 mg orally once daily, or about 50 mg / day to about 100 mg / day.
[0057] In certain embodiments, the therapeutically effective amount is about 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, 350 mg / day, 400 mg / day, 450 mg / day, 500 mg / day, or 600 mg / day.
[0058] In certain embodiments, the therapeutically effective amount is about 30 mg / day, 35 mg / day, 40 mg / day, 45 mg / day, 50 mg / day, 55 mg / day, 60 mg / day, 65 mg / day, 70 mg / day, 75 mg / day, 80 mg / day, 85 mg / day, 90 mg / day, or 95 mg / day.
[0059] In certain embodiments, the therapeutically effective amount is about 150 mg / day, 300 mg / day, or 450 mg / day.
[0060] In another embodiment, Compound 1 is administered orally.
[0061] In another embodiment, the subject experiences greater than 5%, 10%, 20%, or 30% fat loss.
[0062] In another embodiment, a subject with elevated HbAlc levels experiences about 40% fat loss.
[0063] In another embodiment, the subject experiences at least one of the following: i) a reduction in lipids by at least 10% or at least 30%; ii) a reduction in blood pressure of at least 5 mmHg; and / or iii) Reduction of liver fat by at least 50%.
[0064] In another embodiment, the subject experiences at least one of the following: i) a reduction in lipids of at least 10% or at least 30%; ii) a reduction in blood pressure of at least 5 mmHg; and / or iii) Reduction of liver fat by at least 30%.
[0065] In another embodiment, the method slows the progression of obesity, hypertension, or diabetes.
[0066] In one embodiment, the method slows the progression of obesity, hypertension, or diabetes.
[0067] Drug dosage form
[0068] The present disclosure includes novel pharmaceutical dosage forms of Compound 1 or a pharmaceutically acceptable salt thereof. The dosage forms described herein are suitable for oral administration to a subject. The dosage form may be in any form suitable for oral administration, including but not limited to capsules or tablets. In some embodiments, the present disclosure provides a single unit dose of capsules or tablets containing about 30 mg to about 1400 mg, about 100 mg to about 1000 mg, about 150 mg to about 600 mg, or 200 mg to 550 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, Compound 1 is administered in the form of a hydroxypropyl methylcellulose capsule.
[0069] In some embodiments, the amount of Compound 1 in a unit dose is about 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 150 mg, 170 mg, 200 mg, 250 mg, 300 mg, 340 mg, 350 mg, 400 mg, 450 mg, 500 mg, 510 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, or 1400 mg. In some embodiments, the single unit dosage form is a capsule. In some embodiments, the single unit dosage form is a tablet.
[0070] In some embodiments, the amount of compound 1 in a unit dose is about 30 mg, 100 mg, 200 mg, 500 mg, 600 mg, 1050 mg, or 1400 mg. In some embodiments, the amount of compound 1 in a unit dose is about 200 mg, 400 mg, or 550 mg. In some embodiments, the amount of compound 1 in a unit dose is about 170 mg, 340 mg, 510 mg. In some embodiments, the amount of compound 1 in a unit dose is about 150 mg, 300 mg, 450 mg.
[0071] In some embodiments, the amount of Compound 1 in a unit dose is about 30 mg / day, 35 mg / day, 40 mg / day, 45 mg / day, 50 mg / day, 55 mg / day, 60 mg / day, 65 mg / day, 70 mg / day, 75 mg / day, 80 mg / day, 85 mg / day, 90 mg / day, or 95 mg / day. Route of administration
[0072] In therapeutic use for controlling or preventing weight gain in mammals, the compounds of the disclosure or pharmaceutical compositions thereof may be administered orally or parenterally. Example 1: Phase 2a Study of Compound 1 in Subjects with Elevated Liver Fat and High Body Mass Index (BMI)
[0073] This is a 61-day, randomized, double-blind, placebo-controlled trial evaluating the efficacy of tadalafil in patients with nonalcoholic fatty liver disease (NAFLD), elevated liver fat (>8%), and elevated body mass index (BMI) (28 to 45 kg / m 2 The safety and efficacy of 3 doses of orally administered Compound 1 were compared with placebo in subjects with ≥5.7% lipoproteinemia (LPA). Subjects were stratified by glycated hemoglobin (HbA1c ≥ 5.7%). The primary endpoint was the relative change in liver fat content from baseline to day 61 as assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF); secondary endpoints included safety, changes in body composition, body weight, glycemic control, and inflammatory markers.
[0074] Eighty subjects were enrolled (placebo: n=20, compound 1 150mg: n=20, 300mg: n=21, 450mg: n=19). At baseline, 40% of the subjects had elevated HbA1c. At day 61, the absolute and relative reductions in liver fat in compound 1-treated subjects and in the HbA1c subset were highly significant (p<0.0001 compared to placebo). Responder analysis using a 30% or greater reduction in liver fat measured by MRI-PDFF showed that for compound 1 150mg, 300mg and 450mg doses, 40%, 71% and 72% of the subjects responded, respectively, and in the HbA1c subset, 43%, 75% and 86% of the subjects responded, compared to placebo, in 0-5% of the subjects (p<0.05 for all comparisons). Compound 1 treatment was associated with significant reductions in total body fat, body weight, inflammatory markers and glycated albumin. Lean body mass was maintained. No serious adverse events occurred. Six subjects discontinued prematurely, 3 on Compound 1 (150 mg: n=2, 300 mg: n=1) and 3 on placebo. Diarrhea and flushing (most commonly mild) occurred in 35% and 25% of Compound 1 subjects, respectively.
[0075] Study Design
[0076] This is a Phase 2, single-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of Compound 1 in healthy subjects with high BMI and evidence of elevated hepatic fat. Subjects were screened over a 45-day period and eligible subjects were randomized to receive Compound 1 at an oral dose of 150 mg, 300 mg, or 450 mg once daily or matching placebo under fasting conditions for 61 days. Randomization was stratified by glycated hemoglobin A1c (HbA1c), with a normal baseline defined as HbA1c <5.7% and a high baseline defined as HbA1c ≥5.7%. The final follow-up visit was performed within 10 to 14 days after the last dose. See Figure 1 .
[0077] By HbA 1c Randomization will be blocked and stratified. Subjects will be stratified into two HbA1c strata: one subgroup of subjects with normal baseline HbA1c defined as HbA1c <5.7% and another subgroup of subjects with high baseline HbA1c defined as HbA1c between 5.7% and 9.0%, inclusive.
[0078] Target The primary efficacy and safety objectives of this study are to: effect: ■ To evaluate the reduction in liver fat content from baseline to Day 61 as assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in subjects with elevated BMI treated with Compound 1 compared to placebo. Security: ■ To evaluate the safety and tolerability of 61 days of repeated daily dosing of compound in overweight and obese subjects as defined by BMI. The secondary objectives of this study are to: ■ To assess the rate and amount of body weight loss after 61 days of Compound 1 treatment. ■ To evaluate the change from baseline in total body fat gain as measured by MRI after 61 days of Compound 1 treatment. ■ Characterization of the pharmacokinetic (PK) profile of Compound 1 and its metabolites DNP and M1 in subjects with high BMI after 61 days of dosing. ■ To evaluate and correlate changes from baseline in measures of liver composition and changes in liver fat content following dosing with Compound 1. ■Investigate the pharmacodynamic (PD) effects of compound 1 on metabolic and cardiovascular risk factors. ■Study the PD effect of compound 1 on metabolomic, proteomic and lipidomic features, ■ Characterize the dose / exposure relationship of efficacy and PD effects of Compound 1, where data permit.
[0079] Inclusion Criteria To be eligible, subjects must meet all of the following inclusion criteria: 1. Adult male or female, aged 28 to 65 years (inclusive) at the time of signing the informed consent form, and with a BMI between 28.0 and 45.0 kg / m 2 Between (including the end values). a. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative urine pregnancy test at screening, and agree to use effective contraception for at least 4 weeks prior to the first administration of study drug or a barrier method for 2 weeks until 30 days after the last dose of study drug. b. Female subjects of childbearing potential should not donate eggs during the study and for at least 30 days after the last dose of study drug. c. Female subjects of infertile potential must be surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, oophorectomy) or postmenopausal (no menstruation for >1 year and follicle stimulating hormone (FSH) >40U / L at screening). d. Male subjects who have not undergone vasectomy and / or subjects who have undergone vasectomy but have not had 2 post-operative negative sperm tests must agree to use an acceptable method of contraception from the time of the first dose of study drug until 30 days after the last dose of study drug and not to donate sperm during the study and for at least 30 days after the last dose of study drug.
[0080] Exclusion criteria Subjects will be excluded from the study if they meet any of the following criteria: 1. Insulin-controlled diabetes mellitus. 2. Pregnant or breastfeeding or planning to become pregnant. 3. Intolerance to magnetic resonance imaging (MRI) or contraindications to MRI procedures, including but not limited to inability to adapt to the MRI scanner or surgical clips / metal implants / shrapnel. Subjects must not be claustrophobic, have a history of claustrophobia, or be intolerant of enclosed or small spaces. 4. Weight gain or loss >5% in the 3 months prior to the study, or weight gain or loss >10% in the 6 months prior to screening. 5. History of lap banding, intragastric balloon, duodenal jejunal sleeve, or bariatric surgery within 5 years of screening, plan to undergo bariatric surgery before the end of study participation, or plan to lose weight through special diet, exercise program, or both during this study. 6. History of malignant hyperthermia. 7. History of chronic severe recurrent rash of unknown cause. 8. History of clinically significant cardiovascular disease or current clinically significant cardiovascular disease, including but not limited to transient ischemic attack, stroke, arrhythmia, syncope, unstable angina, myocardial infarction within 6 months prior to screening, congestive heart failure, or uncontrolled hypertension. (Uncontrolled hypertension is defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg, based on the average of three resting measurements in the sitting position using an appropriately sized cuff). 9. Resting heart rate <45bpm or >110bpm. 10. Screening ECG or based on medical history: a. Significant baseline prolongation of the QT / QTcF interval (e.g., repeated demonstration of a QTcF interval >450 msec in males and >470 msec in females). b. History of additional risk factors for torsade de pointes (TdP) (eg, heart failure, hypokalemia, family history of long QT syndrome) or family history of unexplained sudden cardiac death. 11. Kidney disease, kidney transplantation, or estimated glomerular filtration rate (eGFR) < 50 mL / min / 1.73 m based on the CKD-EPI creatinine equation (NKF 2009; https: / / www.kidney.org / content / ckd-epi-creatinine-equation-2009) 2 . 12. Significant lung disease requiring long-term daily medication, including chronic obstructive pulmonary disease (COPD), emphysema, pulmonary fibrosis, or asthma. 13. Untreated obesity hypopnea syndrome (OHS) or obstructive sleep apnea (OSA). 14. Active (acute or chronic) liver disease or history other than non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), such as but not limited to autoimmune liver disease, viral hepatitis, hereditary hemochromatosis, primary biliary cirrhosis, Wilson's disease, alpha-1-antitrypsin deficiency, alcoholic liver disease, acute fatty liver of pregnancy, or drug (including acetaminophen)-induced liver disease. 15. History of or treatment for clinically significant gastroparesis, inflammatory bowel disease, or any upper gastrointestinal surgery (except cholecystectomy or minor gastric surgery approved by the Medical Monitor). 16. History of cirrhosis and / or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding. 17. History of acute pancreatitis or chronic pancreatitis of any cause within one year of screening. 18. Serum triglyceride concentration exceeds 500 mg / dL. 19.HbA 1c >9.0%. 20. Family (maternal / paternal / sibling) and / or personal history of retinal detachment at any time in the past. 21. Any history or current diagnosis of glaucoma. 22. Evidence of the following regarding screening eye examinations: a. Peripheral retinal disease requiring treatment, retinal breaks requiring treatment, or lattice degeneration. b. Diabetic retinopathy with macular exudates or macular edema as shown by optical coherence tomography (OCT) and examination. c. Any active macular disease that affects vision, including macular pucker (epiretinal membrane) and macular degeneration. d. Visually significant cataract as determined by an ophthalmologist. e. Any previous intravitreal injection of anti-VEGF agent for macular degeneration. f. History of previous vitrectomy. 23. History of malignancy within 5 years of screening, except for basal cell or squamous cell skin cancer, cervical cancer in situ, or prostate cancer that does not currently or is not expected to require radiotherapy, chemotherapy, and / or surgical intervention or initiation of hormonal therapy. 24. History of organ transplantation. 25. Received COVID-19 vaccine less than 1 week prior to dosing (Visit 2 / Day 1) and / or plans to receive COVID-19 vaccine during the study period. 26. History of severe drug abuse within one year prior to screening, or frequent use of soft drugs (such as marijuana) within three months prior to the screening visit, or frequent use of hard drugs (such as cocaine, phencyclidine [PCP], opioid derivatives including heroin, and amphetamine derivatives) within one year prior to screening. 27. History of alcoholism in the past 2 years or current evidence of excessive drinking as assessed by screening evaluation using the Alcohol Use Disorders Identification Test (AUDIT, Thompson 2018), and a history of usual drinking exceeding approximately 14 drinking units / week (males) and 7 drinking units / week (females) [1 drinking unit = 4 ounces (120 mL) of wine or 12 ounces (360 mL) of beer or 1 ounce (30 mL) of spirits] within 6 months of screening, as determined by the investigator. 28. Positive urine drug screen for drugs of abuse or positive phosphatidylethanol (PEth) blood test result >100 ng / mL at screening. In the case of a ruling-out PEth value, the subject may be considered for inclusion if the principal investigator and medical monitor agree that the subject's history is inconsistent with alcohol abuse. 29. Current regular use of e-cigarettes or more than 5 cigarettes per week or equivalent. Use of nicotine patches to quit smoking is permitted. 30. The test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV1 / 2) antibody is positive. 31. Neutropenia, defined as an absolute neutrophil count ≤1000 / μL. 32. Serum AST or ALT > 5x upper limit of normal (ULN) at screening. (One repeat test within 7 days may be allowed at the investigator's discretion). 33. Total bilirubin >ULN unless due to Gilbert's syndrome or if considered normal variability in the absence of other clinically relevant liver impairment as approved by the Medical Monitor. 34. International normalized ratio (INR) ≥1.3 at screening, provided there is other evidence of potential severe liver injury. 35. Participating in another clinical trial at the time of screening, or being exposed to any investigational drug (including topical investigational drugs) within 30 days or 5 half-lives (if half-life is known) of screening. 36. No tattoos or body piercings during the study. Any underlying physical or mental medical condition that, in the opinion of the investigator or sponsor, makes the subject less likely to comply with the study requirements or to complete the study. 37. Any situation that the investigator believes will interfere with his / her ability to provide written informed consent, comply with study instructions, or that may confound the interpretation of study results or place subjects at undue risk. 38. Known or potential hypersensitivity to Compound 1 or its excipients. Prohibited drugs (current use): 39. Any herbal supplement, over-the-counter medication, mail-order medication, or prescription medication used for weight loss. 40. Prescription or over-the-counter stimulants, including: dextroamphetamine / Dexedrine, dextroamphetamine / amphetamine combination products / Adderall, or methylphenidate 41. Thiazolidinediones (TZDs): pioglitazone / Actos, rosiglitazone / Avandia. 42. Glucagon-like peptide 1 (GLP1) agonists: Exenatide / Byetta / Bydureon, Lixisenatide / Adlyxin, Liraglutide / Victoza, Dulaglutide / Trulicity, Semaglutide / Ozempic. 43. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: canagliflozin / Invokana, dapagliflozin / Farxiga, empagliflozin / Jardiance, erigoflozin / Steglatro. 44. Vitamin E: Use of ursodeoxycholic acid or high-dose vitamin E >400 IU / day for at least one month within the past 6 months, or initiation of high-dose vitamin E within the last 3 months of screening. 45. Recent (within 3 months of screening) or current use of obeticholic acid / Ocaliva, systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines. 46. Warfarin, heparin, factor Xa inhibitors (dabigatran, betrixaban, edoxaban, apixaban, and rivaroxaban). 47. Concomitant medications that prolong the QT / QTc interval and are known to be associated with an increased risk of Torsades de Pointes, as identified in the “Known Risks” category of the https: / / crediblemeds.org / website listing. 48. Products containing cannabidiol (CBD).
[0081] Phase 2a trial results The Phase 2a metabolic trial of Compound 1 was a 61-day randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of three dose levels of Compound 1 (150 mg, 300 mg, and 450 mg) in obese participants (BMI 28 to 45 kg / m2) with elevated liver fat (greater than 8%). 2) in a Phase 2a trial. Eighty (80) participants, ranging in age from 28 to 65 years, were randomized to one of three Compound 1 treatment groups or a matching placebo group, stratified and grouped for HbA1C levels of 5.7% or higher, and dosed once daily (fasting). Participants were instructed not to change their behavior in terms of diet or exercise. The Phase 2a trial met the primary (reduction in liver fat as measured by MRI-PDFF) and secondary (reduction in weight and fat as measured by abdominal MRI) endpoints. Key results and observations include: ●Without changes in eating or exercise behavior, weight loss is almost entirely from fat loss. Lean body mass was maintained at all dosing levels at eight weeks. o Weight and fat loss was greatest at the highest dosing level, with participants losing an average of 6 pounds (p<0.001, high dose vs. placebo). o Participants with elevated HbA1C levels experienced greater weight and fat loss, with an average loss of 10 pounds (p<0.0001, high dose vs. placebo). o Fat reduction was observed in the liver, visceral, and subcutaneous compartments by MRI. ○ Absolute reductions in liver fat >30% were observed by MRI-PDFF: 40%, 71%, and 72% for Compound 1 at the 150 mg, 300 mg, and 450 mg dose levels, respectively, and in the HbA1c subset were 43%, 75%, and 86% for Compound 1 doses, respectively, compared to 0-5% for placebo (P<0.05 for all). ○ Relative reductions in liver fat were 33%, 43%, and 40% at the low, medium, and high doses, respectively, compared to a 2% relative reduction in liver fat and a 5% response rate with placebo, corresponding to response rates (>30% relative reduction) of 40%, 71%, and 72%. Compound 1 was well tolerated at all dose levels with excellent compliance. No serious adverse events or deaths were reported. Diarrhea and transient flushing associated with alcohol ingestion, which occurred in 25% and 31.6% of Compound 1 subjects, respectively, were the most commonly reported adverse events during treatment. Most of these events were mild; in the low-dose group, one participant discontinued Compound 1 due to diarrhea, while at the high dose, no participants discontinued for any reason. Short-term treatment with Compound 1 was associated with significant improvements in each of the primary and secondary endpoints involving NAFLD and obesity. The safety and tolerability of Compound 1, combined with its ability to reduce liver and systemic fat gain in subjects regardless of HbA1c status, suggests that long-term treatment with Compound 1 has the potential to be an effective treatment for NAFLD and other obesity-related metabolic diseases. 150mg, 300mg and 450mg of compound 1 showed significant dose-related positive effects on the primary efficacy endpoint of changes in liver fat content measured by MRI-PDFF compared to baseline in the overall population and in the population with elevated HbA1c, and these changes occurred within 61 days of treatment. In the case of using compound 1, the placebo-corrected changes compared to baseline were in the range of 06& to -7%, which is favorable compared to other short-term Phase 2 studies of drugs for NAFLD (Harrison et al., 2021; Loomba et al., 2020). Based on MRI-PDFF, approximately 60% of the subjects in the overall population and 68% of the subjects in the subgroup experienced at least 30% reduction in liver fat, and for the subjects in the overall population, the placebo-corrected average percentage change compared to baseline was in the range of -33% to 43%, and for the subjects in the subgroup, it was -42% to -50%. The reduction in liver fat content was accompanied by a reduction in body weight, which was caused by body fat, rather than lean body weight loss. Improvements in liver volume, SAT, and CAP scores occurred with Compound 1 in the overall group and in the subgroup with elevated HbA1c. At 300 mg and 450 mg doses, Compound 1 exhibited significant positive effects on several endpoints including InBody scale measurements of body weight, body fat mass, and body fat percentage, while having no significant effects on skeletal muscle mass, lean body mass, or dry lean body mass. Compared with placebo, at day 61, the mean body weight of the 450 mg group was reduced by 6 pounds, and the mean body weight of the subgroup of subjects with elevated HbA1c was reduced by 10 pounds, while skeletal muscle mass (as well as lean body mass and dry lean body mass) remained unchanged. Significant reductions in inflammatory and metabolic markers were observed with the use of Compound 1. Glycated albumin was used in this study rather than HbA1c to assess metabolic control because changes in glycated albumin occurred earlier than HbA1c (120 days) and were a better marker of glycemic control in this 61-day study. A 0.5% reduction in HbA1c was observed, with a greater reduction in glycated albumin, which was statistically significant. Preferential fat loss and improved glycemic control in subjects with elevated HbA1c is of interest, and long-term therapy has the potential to improve metabolic and inflammatory health in people with type 2 diabetes and obesity. ●The results showed that treatment with compound 1 improved the FAST score, and this improvement was of a clinically relevant degree, being evident at the lowest dose used (150 mg). The FAST score is a non-invasive test for identifying patients with progressive liver fibrosis. The prevalence of non-alcoholic fatty liver disease is high, especially in obese and type 2 diabetic patient populations. Some patients can tolerate elevated liver fat levels without disease progression, while others progress to NASH. Currently, a definitive diagnosis of NASH requires a liver biopsy and histological scoring, an invasive and time-consuming diagnostic procedure associated with some risks. The challenge of identifying patients with disease progression puts patients at risk of progressing to late-stage NASH without intervention. Fibroscan is a non-invasive, ultrasound-based method of measuring liver elasticity and hardness that provides a measure of fibrosis. Aspartate aminotransferase (AST) is a liver enzyme that can be measured in a blood sample, and its elevated levels indicate liver damage. The combination of Fibroscan and AST levels (FAST score) has been shown to provide a valuable indicator for patients with progressive fibrosis (Woreta et al. PLoS One 2022 Apr 15;17(4):e0266859, https: / / doi.org / 10.1371 / journal.pone.0266859 ). A relatively small decrease in FAST score of 0.2 points has been shown to provide improvements in several clinical measures in patients diagnosed with NASH (Wong et al., J. of Hepatology Vol. 75, pp. S257-S258 2021; Newsome et al., The N England J of Medicine 2021; 384: 1113-24). ● Thus, the present disclosure provides methods for treating a patient with an elevated FAST score, wherein the subject is experiencing disease progression. In some embodiments, the method reduces the patient's FAST score to reduce the risk of disease progression. In some embodiments, disease progression includes progressive fibrosis, progression to NASH and / or progressive fibrosing liver disease NASH, NASH is a form of NAFLD where in addition to fat in the liver, you have liver inflammation and liver damage. The inflammation and liver damage of NASH can cause fibrosis, or scarring, of the liver. NASH can lead to cirrhosis, where the liver is scarred and permanently damaged. Our data further suggests that Compound 1 at lower dose levels is effective for treating patients with HbA1c levels between 5.7%-9.0% who have NASH, a progressive fibrotic liver disease. The specific efficacy and safety results of Phase 2a are shown in the accompanying figures and the table below:
[0082] (1) Treatment resulted in responses (>30% reduction in liver fat as measured by MRI-PDFF) in all dose groups, as shown in Table 1 below: Table 1
[0083] (2) The body fat reduction of the overall group is shown in Table 2 and Figure 2 shown. Table 2 Summary Statistics of Observed Values and Changes from Baseline for Secondary InBody Outcome Measures (FAS Group) InBody Parameters: Body Fat (lbs) Baseline is the last nonmissing value before the first dose of study drug
[0084] (3) Changes in body fat in the group with elevated HbA1c (mean ± SEM) are shown in Table 3 and Figure 3 shown. Table 3 Summary Statistics for Observed Values and Changes from Baseline for Secondary InBody Measures for Subjects in the HbA1c 5.7%-9.0% Subgroup Only (FAS Population) InBody Parameters: Body Fat (lbs) Baseline is the last nonmissing value before the first dose of study drug
[0085] (4) Maintenance of skeletal muscle mass is shown in Table 4 below: Table 4 InBody Parameter: Skeletal Muscle Mass (lbs)
[0086] (5) Changes in MRI-proton density fat fraction (%) from baseline to Day 61 in all subjects and the subgroup of subjects with elevated HbA1c are shown in Table 5. Table 5
[0087] (6) The percentage change (%) of glycated albumin from baseline to day 61 is shown in Table 6 and Figure 4 shown. Table 6 Summary statistics of observed values and changes from baseline in percentage (%) of glycated albumin by treatment group FAS Group Baseline is the last nonmissing value before the first dose of study drug Summary statistics for observed values of glycated albumin percentage (%) and change from baseline values by treatment group in the HbA1c 5.7%-9.0% subgroup only (FAS population) Baseline is the last nonmissing value before the first dose of study drug
[0088] (7) MMRM analysis of body fat mass, body fat percentage, lean body mass, and changes from baseline to day 61 for all subjects and subgroups of subjects with elevated HbA1c Figure 5 and Figure 6 and are shown in Table 7. Table 7 LS means change from baseline and associated 95% CI, LS mean differences and associated 95% CI, and two-sided p values were derived from the MMRM model with treatment as fixed effect, baseline HbA1c stratification as factor, and baseline parameter value as covariate. Weight loss was achieved in subjects administered Compound 1 without a corresponding loss in lean body mass, ie, the overall observed weight loss was primarily due to fat loss, and the therapeutic effect can be attributed entirely to fat loss. Not only was weight loss more pronounced in participants with elevated HbA1c (all participants with HbA1c>5.7 at baseline, totaling approximately 40% across all cohorts), but the weight loss was even more fat-specific, as no decrease in muscle mass compared to baseline was observed, and an increase in muscle mass was achieved compared to placebo.
[0089] In addition, the 300 mg and 450 mg doses of Compound 1 showed significant positive effects on several secondary endpoints, including InBody scale measurements of body weight, body fat mass, and body fat percentage, without any effect on skeletal muscle mass, lean body mass, or dry lean body mass. Compared with placebo, on day 61, the average body weight of the 450 mg group was reduced by 6 pounds, and the average body weight of the subgroup of subjects with elevated HbA1c was reduced by 10 pounds, while skeletal muscle mass (as well as lean body mass and dry lean body mass) remained unchanged. Significant reductions in inflammatory and metabolic markers were observed with the use of Compound 1. Glycated albumin was used instead of HbA1c to assess metabolic control in this study because changes in glycated albumin occurred earlier than HbA1c (120 days) and were a better marker of glycemic control in this 61-day study. A 0.5% reduction in HbA1c was observed, while the reduction in glycated albumin was greater, which was statistically significant. Preferential fat loss and improved glycemic control in subjects with elevated HbA1c is of interest, and long-term therapy has the potential to improve metabolic and inflammatory health in people with type 2 diabetes and obesity.
Claims
1. A method for maintaining skeletal muscle mass during weight loss in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the weight loss is due to fat loss.
3. The method of claim 1 or 2, wherein the subject suffers from obesity, excess body fat, diabetes, high blood pressure (hypertension), dyslipidemia, hypertriglyceridemia, acquired lipodystrophy, hereditary lipodystrophy, partial lipodystrophy, or metabolic syndrome.
4. The method of claim 1 or 2, wherein the subject suffers from obesity or excess body fat.
5. The method of claim 1 or 2, wherein the subject suffers from diabetes.
6. The method of claim 4, wherein the diabetes is type 2 diabetes mellitus (T2DM).
7. The method of claim 1 or 2, wherein the subject suffers from a disorder selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
8. The method of claim 1 or 2, wherein the subject suffers from sarcopenia.
9. The method of claim 1 or 2, wherein the subject suffers from sarcopenic obesity.
10. The method of claim 1 or 2, wherein the subject suffers from decreased muscle mass, loss of muscle mass, muscle weakness, decreased muscle strength, slow walking speed, or difficulty performing normal daily activities.
11. The method of claim 1 or 2, wherein the method slows the progression of obesity, hypertension or diabetes.
12. The method according to any one of the preceding claims, wherein the subject has abnormal HbA1c levels.
13. The method according to any one of the preceding claims, wherein the abnormal HbA1c level is elevated HbA1c.
14. The method of any one of the preceding claims, wherein the subject has a body mass index greater than 28 kg / m2.
15. The method of any of the preceding claims, wherein the therapeutically effective amount is about 30 mg / day to about 1400 mg / day, about 100 mg / day to about 1000 mg / day, about 150 mg / day to about 600 mg / day, 200 mg / day to 550 mg / day, or about 50 mg / day to about 100 mg / day.
16. The method of any one of the preceding claims, wherein the therapeutically effective amount is about 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, 350 mg / day, 400 mg / day, 450 mg / day, 500 mg / day, or 600 mg / day.
17. The method of any one of the preceding claims, wherein the therapeutically effective amount is about 150 mg / day, 300 mg / day, or 450 mg / day.
18. The method of any one of the preceding claims, wherein the therapeutically effective amount is about 30 mg / day, 35 mg / day, 40 mg / day, 45 mg / day, 50 mg / day, 55 mg / day, 60 mg / day, 65 mg / day, 70 mg / day, 75 mg / day, 80 mg / day, 85 mg / day, 90 mg / day, or 95 mg / day.
19. The method according to any one of the preceding claims, wherein 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is administered orally once daily.
20. The method of any of the preceding claims, wherein the subject experiences greater than 5%, 10%, 20%, 30% or 40% fat loss.
21. The method of claim 20, wherein the subject with elevated HbA1c levels experiences approximately 40% fat loss.
22. The method of any one of the preceding claims, wherein the subject experiences at least one of: i) a reduction in lipids of at least 10% or at least 30%; ii) a reduction in blood pressure of at least 5 mmHg; and / or iii) Reduction of liver fat by at least 50%.
23. The method of any one of the preceding claims, wherein the subject experiences at least one of: i) a reduction in lipids of at least 10% or at least 30%; ii) a reduction in blood pressure of at least 5 mmHg; and / or iii) Reduction of liver fat by at least 30%.
